Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Alzheimer's disease

Aliases
Alzheimer Disease

236 clinical trials

227 products

8 drugs

Product
[F-18]Flornaptitril
Clinical trial
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Product
DSPE-DOTA-Gd Liposomal
Product
RB-ADSC
Product
Placebo
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2024-02-13
Clinical trial
A Phase 1, Controlled, Open-label, Single Dose, Dose-escalation, Clinical Proof-of-concept Study of MRI Enhanced With ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in Patients With Brain Amyloid Deposits as Demonstrated by Amyloid PET
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Tricaprilin
Clinical trial
A Phase III, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Product
Buntanetap/Posiphen
Clinical trial
Ph 1, Open-Label Safety Study of Escalating Doses of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous ADSCs in Participants With Mild-Moderate AD Whose Treatment is Not Addressed Adequately by Available Therapy
Status: Recruiting, Estimated PCD: 2025-02-01
Product
GB-5001A
Product
GB-5001D
Product
Oral cohort
Clinical trial
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease (AD)
Status: Recruiting, Estimated PCD: 2025-11-01
Product
PrimeC
Clinical trial
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, and Clinical Efficacy of Seltorexant (JNJ-42847922) on Behavioral and Psychological Symptoms of Dementia in Patients With Probable Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-11-10
Product
Seltorexant
Product
AL002
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-09-17
Clinical trial
An Open-label, Active-controlled, Parallel and Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers
Status: Recruiting, Estimated PCD: 2024-09-17
Clinical trial
Multicenter Randomized Double-blind Placebo-controlled Three-arm Parallel-group Clinical Study to Evaluate the Efficacy and Safety of DMB-I in the Treatment of Dementia Associated With Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-12-21
Product
DMB-I
Product
LY3372993
Clinical trial
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Product
[18F]PI-2620
Clinical trial
An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2025-03-07
Product
Gantenerumab
Product
JNJ-63733657
Clinical trial
A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Pharmacodynamic Effects of Once Weekly Administration of Gantenerumab in Participants With Early (Prodromal to Mild) Alzheimer's Disease
Status: Terminated, Estimated PCD: 2023-01-11
Clinical trial
Individual Patient Expanded Access Investigation New Drug (IND) Application for Administration of Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease
Status:
Product
Adipose-Derived Mesenchymal Stem Cells
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
Simufilam
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Tau PET Longitudinal Substudy Associated With: A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-randomized, Placebo-treated Non-carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-04-19
Product
Crenezumab
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease
Status: Terminated, Estimated PCD: 2022-09-23
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Masupirdine
Product
NIO752
Clinical trial
A Randomized, Participant and Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of a Single Intrathecally Administered Dose of NIO752 to Lower Cerebrospinal Fluid Total Tau Levels in Participants With Early Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2025-10-21
Product
Matching placebo
Clinical trial
An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease
Status: Terminated, Estimated PCD: 2023-01-04
Product
AR1001
Clinical trial
A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD)
Status: Recruiting, Estimated PCD: 2025-12-01
Product
ALZ-101
Product
Choline Alfoscerate
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Patients With Mild to Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease
Status: Terminated, Estimated PCD: 2022-12-28
Product
SNK01
Clinical trial
Single Center, Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects With Alzheimer's Disease (AD)
Status: Terminated, Estimated PCD: 2023-08-16
Clinical trial
A 12-Month, Open-Label Safety Study of Simufilam Followed by a 6-Month Randomized Withdrawal and 6 Additional Months Open-Label in Mild-to-moderate Alzheimer's Disease Patients
Status: Completed, Estimated PCD: 2023-11-09
Product
MK-2214
Clinical trial
A Multiple Ascending Dose Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-05-16
Clinical trial
A Double-blind, Randomized, Parallel-group Multiple Dose Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-01-15
Clinical trial
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2023-04-14
Product
Donanemab
Clinical trial
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.
Status: Completed, Estimated PCD: 2021-06-30
Product
ALIA-1758
Product
XPro1595
Product
ATH-1017
Clinical trial
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2027-11-08
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single Ascending Dose Trial to Assess the Safety, Tolerability and Pharmacokinetic Effects of ALIA-1758 in Healthy Participants
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
DDN-A-0101
Clinical trial
A Dose-blocked-randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of DDN-A-0101 in Healthy Adults and Elderly Subjects
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Exploratory PLatform Trial on Anti-Inflammatory Agents in Alzheimer's Disease (EXPLAIN-AD): A Randomized, Placebo-controlled, Multicenter Platform Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Various Anti-inflammatory Agents in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Status: Terminated, Estimated PCD: 2024-03-07
Product
Canakinumab
Clinical trial
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-07-09
Product
LY3372689
Product
TW001
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients
Status: Recruiting, Estimated PCD: 2024-01-01
Product
BMS-986446
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Global, Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease (TargetTau-1)
Status: Recruiting, Estimated PCD: 2027-08-31
Product
Donepezil
Clinical trial
A Single-center, Open-label, Single-dose Ascending Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetic Profile of HHT201 (Donepezil Dihydroxynaphthalate for Injection) in Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2025-03-31
Product
AXS-05
Clinical trial
ADVANCE-2: Addressing Dementia Via Agitation-Centered Evaluation 2: A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Alzheimer's Disease Agitation
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)
Status: Recruiting, Estimated PCD: 2024-09-30
Product
BI 409306
Clinical trial
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Completed, Estimated PCD: 2017-08-03
Product
PQ912
Clinical trial
Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2027-04-16
Product
ACU193
Clinical trial
A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2031-01-01
Clinical trial
A Phase 2b, Double-Blind, Placebo-Controlled, Parallel-Groups, 36-Week, 2-Arm Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg Daily in Patients With Mild or Moderate Dementia Due to Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Xanamem
Clinical trial
An Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY2287411 Injection, in Patients With Solid Tumors Known to Express Mesothelin
Status: Completed, Estimated PCD: 2021-09-29
Product
Flortaucipir F18
Product
LY3954068
Clinical trial
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
Status: , Estimated PCD: 2024-12-01
Product
ALZN002
Clinical trial
Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1/2a Study to Assess Safety, Tolerability & Efficacy of Autologous Beta-Amyloid Mutant Peptide-pulsed Dendritic Cells in Subjects With Mild-to-Moderate Alzheimer's Dementia
Status: Active (not recruiting), Estimated PCD: 2028-03-03
Product
Donepezil Dihydroxynaphthalate
Product
AstroStem
Clinical trial
An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status: Completed, Estimated PCD: 2021-09-21
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment
Status: Completed, Estimated PCD: 2022-03-31
Clinical trial
A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2024-03-13
Product
Montelukast
Product
LX1001
Clinical trial
An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease
Status: Terminated, Estimated PCD: 2023-03-06
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer's Disease
Status: Not yet recruiting, Estimated PCD: 2024-05-30
Product
SAGE-718
Clinical trial
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 as Add-on to Acetylcholine Esterase Inhibitors in Subjects With Mild Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-07-19
Clinical trial
Expanded Access With TB006 Treatment in Adults With Alzheimer's Disease and Related Dementias
Status:
Clinical trial
A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum
Status: Terminated, Estimated PCD: 2018-06-28
Product
JNJ-54861911
Clinical trial
An Open-label, Multicenter, Controlled Pharmaco-dynamic Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease in Comparison to Healthy Volunteers
Status: Completed, Estimated PCD: 2021-07-12
Product
T3D-959
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-01-20
Clinical trial
A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
Status: Completed, Estimated PCD: 2021-06-20
Clinical trial
PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study
Status: Terminated, Estimated PCD: 2019-06-10
Product
GV-971
Clinical trial
A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)
Status: , Estimated PCD: 2025-12-01
Product
EX039
Clinical trial
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type
Status: Completed, Estimated PCD: 2020-04-17
Product
Bupropion
Product
TB006
Product
TEP
Product
REM0046127
Product
PU-AD
Clinical trial
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-01-01
Product
Lu AF87908
Product
COR388
Product
IGC AD1
Clinical trial
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Status: Completed, Estimated PCD: 2020-12-04
Product
Placebos
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-06-07
Product
LY3202626
Clinical trial
Long-Term Follow-Up to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2028-11-01
Product
ACD856
Product
TRx0237
Product
EGb 761
Clinical trial
A Phase 0, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics of a Single Intravenous Microdose of ACD856 in Healthy Volunteers
Status: Completed, Estimated PCD: 2020-04-18
Clinical trial
Effect of EGb 761® on the Ratio of the Isoforms of the Protein Precursor of Beta Amyloid Platelets on Patients With Mild to Moderate Alzheimer's Disease. A Phase II, Randomised, Double-blind Trial, on Parallel Groups Versus Placebo.
Status: Terminated, Estimated PCD: 2008-04-01
Product
Florbetapir F 18 PET Scan
Clinical trial
A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Status: Completed, Estimated PCD: 2022-05-23
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of APNmAb005 in Healthy Subjects
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Product
OLX-07010
Clinical trial
Phase 1 Randomized, Double-Blind, Single Ascending Dose, Multiple Ascending Dose, and Food Effect Study of the Safety, Tolerability, and Pharmacokinetics of OLX-07010 in Healthy Adult and Elderly Participants
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C] CT1812 in Healthy Adult Male Subjects
Status: Completed, Estimated PCD: 2022-01-17
Product
Aricept
Product
IVL3003
Product
CT1812
Clinical trial
A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-03-31
Product
NNI-362
Clinical trial
Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age
Status: Completed, Estimated PCD: 2021-07-31
Product
Bryostatin
Clinical trial
A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2020-10-16
Product
APNmAb005
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Status: Completed, Estimated PCD: 2022-11-16
Clinical trial
Open-Label Extension of Studies ATH-1017-AD-0201 and ATH-1017-AD-0202 in Subjects With Mild to Moderate Alzheimer's Disease
Status: , Estimated PCD: 2027-01-01
Product
Brexpiprazole
Product
NPT 2042
Product
Masitinib
Clinical trial
A Single-center, Randomized, Placebo Controlled, Double-blind, Ascending Single-dose and Repeated-dose Trial to Determine the Safety and Pharmacokinetic Profile of NPT 2042 Soft-Gelatin Capsules Administered Orally to Healthy Adult Subjects
Status: Completed, Estimated PCD: 2023-03-17
Clinical trial
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease: Intermediate-Size Patient Population
Status:
Product
AC-OLE-01-VA
Product
Standard of care
Product
E2020
Clinical trial
Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study With an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
Status: Completed, Estimated PCD: 2015-01-01
Clinical trial
An Open Label Extension of XPro1595 in Patients With Alzheimer's Disease That Have Completed a Phase 1 or Phase 2 Study With XPro1595
Status: Recruiting, Estimated PCD: 2026-05-04
Clinical trial
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Status: Active (not recruiting), Estimated PCD: 2021-01-30
Clinical trial
A Phase 1, Open-label Study to Evaluate the Tolerability of 21 Days of Treatment With the AC-OLE-01-VA Formulation of Tricaprilin Under Different Dosing Conditions in Healthy Participants
Status: Completed, Estimated PCD: 2022-12-22
Clinical trial
A Randomized, Open-label, 2-period, Crossover, Pilot Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers
Status: Active (not recruiting), Estimated PCD: 2023-02-27
Clinical trial
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-09-09
Product
Aducanumab
Clinical trial
A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-05-20
Clinical trial
A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease: Double-Blind, Randomized Between Placebo Control Group and Dose Groups, Parallel-Design, Multicenter Study
Status: Recruiting, Estimated PCD: 2021-02-24
Product
PM012
Clinical trial
A Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type
Status: Completed, Estimated PCD: 2022-11-21
Product
BMS-984923
Clinical trial
A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-04-26
Product
troriluzole
Clinical trial
A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2020-12-15
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study of Masitinib as add-on Therapy in Patients With Mild to Moderate Alzheimer's Disease
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Product
E2814
Clinical trial
A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of Inflammation
Status: Withdrawn, Estimated PCD: 2023-10-26
Clinical trial
An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-07-14
Clinical trial
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2019-06-05
Product
Florbetapir F 18
Product
LY3303560
Product
Flortaucipir
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 Intramuscular Depot and Aricept® Oral Tablets (Pfizer Canada Inc.) in Healthy Male Volunteers
Status: Completed, Estimated PCD: 2023-06-02
Product
GB-5001
Clinical trial
A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Oral ASN51 in Healthy Young Adult and Elderly Subjects and Elderly Subjects With Alzheimer's Disease
Status: Terminated, Estimated PCD: 2022-08-01
Product
ASN51
Product
Sodium Oligomannate
Clinical trial
A Clinical Study to Evaluate the Long-term Efficacy and Safety of Sodium Oligomannate Capsules (GV-971)
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Product
ANAVEX2-73
Clinical trial
A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin, and Matching Placebo to Include Single-dose and Food Effect (Part A), and Titration Tolerability (Part B), in Healthy Subjects
Status: Completed, Estimated PCD: 2022-08-13
Product
AC-1202
Clinical trial
An Open Label, Single Center Study to Evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Mild to Moderate Alzheimer's Disease (AD) and Patients With Progressive Supranuclear Palsy (PSP) After i.v. Application of [18F]PI-2620 With High and Low Specific Activity
Status: Active (not recruiting), Estimated PCD: 2022-10-26
Clinical trial
A 52-Week, Multicenter, Phase 1/2 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
[18F]-PI2620
Clinical trial
A Phase 1, Three-part, Part-randomised, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Different Formulations of Tricaprilin, to Include Single-dose, Food Effect, and Titration Tolerability, in Healthy Participants
Status: Terminated, Estimated PCD: 2022-03-18
Product
AC-OLE-01
Product
AC-OLE-02
Product
AC-OLE-03
Product
AC-OLE-04
Product
AC-OLE-05
Product
AC-OLE-06
Product
AC-OLE-07
Product
AC-OLE-08
Product
AC-OLE-09
Product
AC-OLE-010
Product
AC-OLE-P
Clinical trial
A Phase 1 Study to Assess the Pharmacokinetics of Different Multiple Dose Regimens of CT1812 in Older Healthy Volunteers
Status: Completed, Estimated PCD: 2022-06-01
Product
REM0046127 High Dose
Product
Pepinemab
Clinical trial
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD
Status: Active (not recruiting), Estimated PCD: 2023-06-05
Clinical trial
A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-06-12
Clinical trial
A Randomized, Participant & Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of Intrathecally Administered NIO752 to Lower CSF Total Tau Synthesis in Participants With AD Measured by Stable Isotope Labelling Kinetics
Status: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
Status: Recruiting, Estimated PCD: 2027-02-01
Product
Benfotiamine
Clinical trial
F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (IND 123119, Protocol D
Status: , Estimated PCD: 2024-03-01
Product
F 18 T807
Clinical trial
Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
F18-3F4AP
Clinical trial
Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway (CARPE DIEM)
Status: Completed, Estimated PCD: 2022-01-13
Drug
sirolimus
Clinical trial
Safety, Tolerability and Pharmacokinetics of AD16 Tablets After Multiple Administration in Healthy Chinese Adult Subjects
Status: Completed, Estimated PCD: 2020-07-31
Product
AD16
Product
AD16 Placebo
Clinical trial
Testing Whether Choline Normalizes Lipid Metabolism in APOE4 Carriers
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Choline
Clinical trial
Open-Label Trial of a Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
Status: Recruiting, Estimated PCD: 2024-09-15
Product
High CBD/Low THC Sublingual Solution
Clinical trial
Imaging Biomarkers in Preclinical and Symptomatic AD. (ACS PiB IND)
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Pittsburgh Compound-B
Clinical trial
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Product
18-F-Flortaucipir
Clinical trial
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
Status: Recruiting, Estimated PCD: 2026-03-01
Product
F-18 AV 1451
Product
C-11 PiB
Clinical trial
Exploratory Evaluation of [11C]MPC6827 Pharmacokinetics With Positron Emission Tomography (PET)
Status: Recruiting, Estimated PCD: 2024-09-01
Product
[11C]MPC6827
Clinical trial
Donepezil Use Versus Non-drug Approach in Treatment of Newly Diagnosed Alzheimer's Disease : a Multicentric, Randomized, Open Study : the CHOLINE-2 Study
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
Cause or Effect: Untangling the Relationship With Amyloid and Tau Deposits to Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
Status: Completed, Estimated PCD: 2022-06-30
Product
[18F]AV-1451
Clinical trial
Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease: The ExPlas Study
Status: Recruiting, Estimated PCD: 2024-09-01
Product
ExPlas
Product
Octaplasma
Drug
Varlilumab
Clinical trial
Randomised Clinical Trial of Noradrenergic Add-on Therapy With Extended-Release Guanfacine in Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-08-05
Product
Guanfacine
Clinical trial
Developing Advanced Blood-Brain Barrier Permeability Imaging for Early Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-01-28
Product
Gadolinium-based Contrast Agent for MRI
Clinical trial
The Use of Memantine for Prevention of Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Memantine
Clinical trial
Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study
Status: Recruiting, Estimated PCD: 2027-12-01
Product
Semaglutide
Clinical trial
Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?
Status: , Estimated PCD: 2024-07-01
Product
BCG vaccine
Clinical trial
Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease
Status: , Estimated PCD: 2024-04-16
Product
11C-ER176
Product
[F-18]MK-6240
Product
Florbetaben
Clinical trial
Effect of Pulsatile GnRH Therapy on Cognition in Down Syndrome: Randomized Placebo Control Study
Status: Recruiting, Estimated PCD: 2028-12-01
Product
GnRH
Product
0.9% NaCl
Clinical trial
Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography (ERAP)
Status: , Estimated PCD: 2025-01-31
Product
Sirolimus
Clinical trial
Rapamycin - Effects on Alzheimer's and Cognitive Health (REACH)
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Rapamycin
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center II Clinical Trial to Evaluate the Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Mild to Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-11-30
Product
Wei Li Bai
Product
Wei Li Bai capsules
Clinical trial
Cognitive Neurology Unit's Anti-amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease Clinical Registry
Status: Recruiting, Estimated PCD: 2028-06-01
Product
Lecanemab
Clinical trial
Multimodal Assessment of Cognitive Impairment in Alzheimer Patients
Status: Not yet recruiting, Estimated PCD: 2030-12-29
Product
Blood samples
Clinical trial
Longitudinal Evaluation of [18-F]MK-6240 as a Novel Tau PET Radiotracer in Patients With Alzheimer's Disease Dementia or Mild Cognitive Impairment Compared to Healthy Volunteers
Status: Completed, Estimated PCD: 2022-05-19
Product
All Subjects
Product
Fecal samples
Clinical trial
Effect of a Dual Orexin Receptor Antagonist on CSF Alzheimer's Disease Biomarkers
Status: Recruiting, Estimated PCD: 2029-03-11
Product
Lemborexant
Clinical trial
A Phase I, Randomized, Double-Blind Study to Evaluate Safety and Tolerability of Amyloid-β Vaccine, AV-1959D, in Patients With Early Alzheimer's Disease.
Status: Recruiting, Estimated PCD: 2026-02-20
Product
AV-1959D
Clinical trial
Beta Amyloid PET Imaging for Alzheimer Disease: [18F]-Fluselenamyl (Alternative Vehicle) Comparison With [11C]-PIB (FSA-PIB AD)
Status: Recruiting, Estimated PCD: 2025-11-01
Product
18F-Fluselenamyl
Clinical trial
Safety and Pharmacokinetics of a Novel NMDA Receptor Antagonist Against Brain Related Diseases in Healthy Adult Volunteers: First-in-human, Phase I, Single Dose-escalating, Open Label Study
Status: Withdrawn, Estimated PCD: 2024-05-02
Product
Fluoroethylnormemantine
Clinical trial
Efficacy, Safety and Response Predictors of Adjuvant Astragalus for Cognition in Alzheimer Disease With Orthostatic Hypotension: an add-on, Assessor-blind, Pragmatic Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-05-30
Product
Astragalus
Clinical trial
Amyloid Brain Positron Emission Tomography (PET) Imaging With 11C-PIB and Tau PET Imaging With 18F-MK-6240 in the Diabetes Prevention Program Outcomes Study.
Status: Terminated, Estimated PCD: 2023-01-31
Product
18F-MK-6240
Clinical trial
Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease
Status: Recruiting, Estimated PCD: 2025-11-01
Product
11C-PIB
Clinical trial
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease (SESAD)
Status: Recruiting, Estimated PCD: 2025-07-31
Product
Sargramostim
Clinical trial
Study of Nasal Insulin to Fight Forgetfulness - Combination Intranasal Insulin and Empagliflozin Trial
Status: Recruiting, Estimated PCD: 2026-10-01
Product
Insulin (Humulin R U-100)
Product
Empagliflozin
Product
Saline
Clinical trial
Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Dasatinib + Quercetin
Clinical trial
A Single-center, Observational, Longitudinal Study on the Effect of Slow Wave Sleep (SWS) Characteristics and Race and Ethnicity on Amyloid Burden (a Marker of Alzheimer's Disease Risk), Among Cognitively Normal Elderly
Status: Recruiting, Estimated PCD: 2024-06-01
Product
PiB
Clinical trial
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study
Status: Completed, Estimated PCD: 2022-03-21
Product
Levetiracetam
Clinical trial
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia
Status: , Estimated PCD: 2025-03-01
Product
C-11 ER-176
Clinical trial
Georgia Memory Net Center for Medicare and Medicaid Services Registry for Anti-Amyloid Monoclonal Antibody Coverage With Evidence Development
Status: Recruiting, Estimated PCD: 2028-07-01
Product
Anti-amyloid Monoclonal Antibodies
Product
Standard of Care
Clinical trial
Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
Status: Withdrawn, Estimated PCD: 2023-09-27
Clinical trial
11C-PIB PET Study in the Multi Ethnic Study of Atherosclerosis at Columbia University
Status: , Estimated PCD: 2025-06-30
Clinical trial
Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease
Status: Recruiting, Estimated PCD: 2026-05-13
Product
Daridorexant
Product
Intranasal insulin
Clinical trial
Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)
Status: Recruiting, Estimated PCD: 2024-12-01
Product
methylphenidate
Clinical trial
Investigation of Inflammation Using [C-11]-CS1P1
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Product
[11C]-CS1P1
Clinical trial
ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease
Status: , Estimated PCD: 2024-12-01
Product
Dasatinib
Product
Quercetin
Clinical trial
Impact of SSRIs on the Rate of Progression of Patients With Mild Cognitive Impairment to Alzheimer's Disease Dementia and Other Neurodegenerative Dementias, With or Without Concurrent Use of Acetylcholinesterase Inhibitors
Status: Withdrawn, Estimated PCD: 2023-10-06
Product
SSRI
Clinical trial
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
Status: Completed, Estimated PCD: 2023-07-14
Product
18F-Florbetaben
Clinical trial
An Open-label, Non-randomized, Single-center Study, Evaluating the Imaging Characteristics of XTR006 Injection in Non-cognitively Impaired Subjects, MCI Due to Alzheimer Disease (AD), and Mild to Moderate AD Subjects
Status: Completed, Estimated PCD: 2023-11-28
Product
XTR006
Clinical trial
Depression Treatment and Aβ Dynamics: A Study of Alzheimer's Disease Risk (ABD Study)
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Escitalopram
Clinical trial
A Randomised, Placebo-controlled, Single-blind Study to Characterise the Biomarker Effects of the Colony Stimulating Factor-1 (CSF-1) Receptor Antagonist JNJ-40346527 in Participants With Mild Cognitive Impairment
Status: Terminated, Estimated PCD: 2022-02-18
Product
JNJ-40346527
Clinical trial
PBR28 Brain Positron Emission Tomography Imaging With Lipopolysaccharide (LPS) Challenge for the Study of Microglia Function in Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-07-27
Product
LPS
Clinical trial
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Proof of Concept Trial Including Asymptomatic Individuals Using Baricitinib
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Baricitinib
Clinical trial
A Placebo Controlled Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Early Alzheimer's Disease (FEAD)
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Product
Fasudil
Clinical trial
Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Allopregnanolone
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Mild and Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-06-30
Product
Flos gossypii flavonoids
Clinical trial
Plasma Dilution and Infusion to Improve Cognition in Mild Cognitive Impairment (MCI)
Status: , Estimated PCD: 2024-12-31
Product
Plasma exchange
Clinical trial
Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease: Multicenter Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in the Brains of Healthy Controls and Patients With Dementia.
Status: Recruiting, Estimated PCD: 2024-11-02
Product
[18F]RP-115
Clinical trial
Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Senicapoc
Clinical trial
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Status: Completed, Estimated PCD: 2024-02-27
Clinical trial
Anti-viral Therapy in Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Valacyclovir
Clinical trial
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-09-01
Product
Spironolactone
Clinical trial
Sleep Trial to Prevent Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2026-05-01
Product
Suvorexant
Clinical trial
F 18 T807 Tau PET Imaging of Frontotemporal Dementia
Status: Withdrawn, Estimated PCD: 2020-09-30
Clinical trial
Phase II Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)
Status: Recruiting, Estimated PCD: 2025-06-30
Product
CORT108297
Clinical trial
Nabilone for Agitation Blinded Intervention Trial
Status: Recruiting, Estimated PCD: 2025-10-01
Product
Nabilone
Clinical trial
Immunohistochemical Study of Peripheral Blood Mononuclear Cells in Sporadic Alzheimer's Disease and Dementia With Lewy Body
Status: Recruiting, Estimated PCD: 2023-12-01
Product
Cytof in PBMC
Clinical trial
Central and Peripheral Immune Cross-talk in Alzheimer's Disease and Their Modulation by a Novel Immunotherapy
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers. (IND 123119, Protocol Z)
Status: Withdrawn, Estimated PCD: 2022-10-11
Product
F 18 T807 Flortaucipir
Clinical trial
Clinical Trial to Determine the Effects of Statins on Brain Health - STAREE-Mind Imaging Substudy
Status: Active (not recruiting), Estimated PCD: 2026-09-01
Product
Atorvastatin
Clinical trial
The Delivery of Essential Fatty Acids to the Brain
Status: Completed, Estimated PCD: 2024-05-16
Product
DHA
Clinical trial
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition
Status: Recruiting, Estimated PCD: 2024-08-28
Product
FEOBV
Clinical trial
Director of Nuclear Medicine Department
Status: Recruiting, Estimated PCD: 2024-09-10
Product
[18F]APN-1607
Clinical trial
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
Status: Recruiting, Estimated PCD: 2026-04-01
Product
[C-11]PiB-PET/MRI
Clinical trial
Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-12-30
Product
Psilocybin
Clinical trial
Evaluation of in Vivo Neuroinflammation in Alzheimer's Disease Using Novel Positron Emission Tomography (PET/CT) Imaging
Status: Recruiting, Estimated PCD: 2025-03-01
Product
[18F]NOS
Product
[11C]PBR28
Clinical trial
Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjectives With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease
Status: Completed, Estimated PCD: 2021-02-28
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single Dose Escalation of CM383 in Male Healthy Subjects
Status: Not yet recruiting, Estimated PCD: 2025-06-30
Product
CM383
Clinical trial
A Phase I, Prospective, Open-label Trial to Evaluate the Safety, Tolerability and Exploratory Outcomes of Multiple Allogeneic Human Mesenchymal Stem Cells (HMSC) Infusions in Patients With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-04-25
Product
Allogeneic hMSC
Clinical trial
Epileptic Hippocampus in Alzheimer's Disease
Status: Not yet recruiting, Estimated PCD: 2028-06-01
Product
Brivaracetam
Clinical trial
A Pilot, Multiple Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Use of Methylphenidate for Cognitive and Behavioral Symptoms in Mild Cognitive Impairment and Dementia
Status: Completed, Estimated PCD: 2021-08-30
Product
Methylphenidate
Clinical trial
Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
Status: Recruiting, Estimated PCD: 2024-03-31
Product
Emtriva
Clinical trial
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
Status: Recruiting, Estimated PCD: 2025-11-01
Product
[11C]-Pittsburgh Compound B
Clinical trial
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Pramlintide
Product
F 18 AV-1451
Clinical trial
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease (ART-AD)
Status: Active (not recruiting), Estimated PCD: 2023-05-04
Product
3TC
Clinical trial
Randomized Controlled Pilot Trial Of Dapagliflozin In Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-07-07
Drug
Dapagliflozin
Clinical trial
Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD in Humans
Status: Completed, Estimated PCD: 2021-05-01
Product
18F-AV-1451
Clinical trial
Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: IV to IM Bridging Study
Status: Active (not recruiting), Estimated PCD: 2022-12-01
Clinical trial
An Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Simufilam 100 mg Tablets in Participants With Mild to Moderate Alzheimer's Disease
Status: , Estimated PCD: 2026-07-15
Clinical trial
F 18 T807 Tau PET Imaging of Alzheimer's Disease [IND# 123119] Protocol A
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
Status: Recruiting, Estimated PCD: 2025-07-08
Product
[F-18]AV-1451-PET
Clinical trial
2-Hydroxybenzylamine (2-HOBA) Phase 1b/2a Proof-of Concept, Dose-Finding, Biomarker Study in Early Alzheimer's Patients
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Product
2-Hydroxybenzylamine
Clinical trial
An Open-Label, Pilot Study of Daratumumab SC in Patients With Mild to Moderate Alzheimer's Disease
Status: Completed, Estimated PCD: 2023-06-08
Product
Daratumumab
Clinical trial
SV2A PET Imaging in Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2023-10-17
Product
UCB-J
Clinical trial
Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment
Status: Terminated, Estimated PCD: 2022-09-23
Product
11C-PiB
Clinical trial
BAY 94-9172 PET/CT in Cognitively Normal Older Adults, Older Adults With Mild Cognitive Impairment, and Older Adults With Alzheimer's Disease
Status: Completed, Estimated PCD: 2014-10-22
Product
BAY 94-9172
Clinical trial
Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients
Status: Completed, Estimated PCD: 2021-04-30
Product
VX-745
Drug
placebo
Clinical trial
Cannabidiol Medication Intervention Trial (CALM-IT)
Status: Recruiting, Estimated PCD: 2026-12-29
Drug
cannabidiol
Clinical trial
Phase I Trial Using Interleukin-2 (IL-2) to Expand Regulatory T Cells in Patients With Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-04-27
Drug
interleukin-2
Clinical trial
Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study
Status: Not yet recruiting, Estimated PCD: 2028-06-01
Product
Blood sampling
Product
Lumbar puncture
Clinical trial
An Open-label Trial to Evaluate the Effects of BCG Immunization on Biomarkers of Inflammation/Immune Response and Alzheimer's Disease in Adults With Mild Cognitive Impairment and Mild-to-Moderate Dementia Due to Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2023-10-01
Product
Bacillus Calmette-Guerin
Clinical trial
Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-03-01
Product
THC-free CBD Oil
Clinical trial
A Proof-of-Concept Clinical Research Study of Efavirenz in Patients With Alzheimer's Disease
Status: Completed, Estimated PCD: 2022-01-28
Product
Sustiva
Clinical trial
Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Product
Definity
Clinical trial
Assess the Brain Levels of Fibrin in Alzheimer's Disease and Its Related Dementias Subjects Using 64Cu-FBP8 PET
Status: Recruiting, Estimated PCD: 2024-09-28
Product
64Cu-FBP8
Clinical trial
A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Adult Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51 Following a Single Oral Dose
Status: Completed, Estimated PCD: 2021-11-02
Clinical trial
Pilot Study to Investigate the Safety and Feasibility of Senolytic Therapy to Modulate Progression of Alzheimer's Disease (SToMP-AD)
Status: Completed, Estimated PCD: 2021-12-10
Clinical trial
An Open-Label, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
Status: Completed, Estimated PCD: 2022-04-24
Clinical trial
Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease:a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clicnial Trial
Status: Recruiting, Estimated PCD: 2024-03-01
Product
Yangxue Qingnao
Product
Yangxue Qingnao pills
Clinical trial
Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Health of the Cholinergic System and Risk for Alzheimer's Disease in Postmenopausal Women
Status: Recruiting, Estimated PCD: 2024-03-31
Product
Cholinergic antagonist
Clinical trial
Effects of Montelukast Therapy on Alzheimer's Disease (EMERALD)
Status: Completed, Estimated PCD: 2022-11-18
Clinical trial
Investigating Brain Insulin Resistance in Alzheimer Disease With Intra-Nasal Insulin Administration: A Multimodal Neuroimaging Study
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Product
Insulin
Clinical trial
Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)
Status: Completed, Estimated PCD: 2023-02-16
Clinical trial
Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease
Status: Not yet recruiting, Estimated PCD: 2026-04-01
Product
l-Histidine
Clinical trial
A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients With Mild to Moderate Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-12-30
Drug
IL-2
Clinical trial
Study of Nasal Insulin to Fight Forgetfulness (SNIFF) - 3-Week Aptar CPS Device
Status: Not yet recruiting, Estimated PCD: 2029-05-01
Clinical trial
Clinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers: A Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2026-11-30
Clinical trial
TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease: Intermediate-Size Patient Population
Status:
Clinical trial
Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD
Status: Recruiting, Estimated PCD: 2025-09-01
Drug
aldesleukin
Clinical trial
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
DAOIB plus AO
Product
DAOIB
Clinical trial
A Randomized Phase II Study to Evaluate Oral RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β in Cognitively Unimpaired Adults
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Product
Resveratrol, Quercetin, and Curcumin (RQC)
Product
Curcumin
Clinical trial
A Phase IIa Proof of Concept, Randomized, Double-blind, Placebo-controlled Study of the Effects of L-serine on Early Stage Alzheimer's Disease Patients
Status: Terminated, Estimated PCD: 2021-07-20
Product
L-Serine